HEMOGENYX PHARMACEUTICALS PLC Logo

HEMOGENYX PHARMACEUTICALS PLC

Develops cell-based therapies for blood, autoimmune diseases, and viral infections.

HEMO | IL

Overview

Corporate Details

ISIN(s):
GB00BYX3WZ24
LEI:
2138008L93GYU5GN6179
Country:
United Kingdom
Address:
6TH FLOOR, 60 GRACECHURCH STREET, EC3V 0HR LONDON

Description

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for life-threatening diseases. The company develops treatments for blood and autoimmune diseases, as well as viral infections. Its core technology includes advanced cell-based therapies, such as its proprietary Chimeric Antigen Receptor (CAR) T-cell platform, HEMO-CAR-T, which is being developed for the potential treatment of Acute Myeloid Leukemia (AML).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-02-28 19:30
Total Voting Rights
English 15.0 KB
2020-02-20 08:00
HEMO-CAR-T cells Effective Against AML in vivo
English 21.2 KB
2020-02-11 08:00
Approval and Issuance of U.S. Hu-PHEC Patent
English 19.9 KB
2020-01-31 08:00
Director/PDMR Shareholding
English 21.4 KB
2020-01-30 15:05
Placing and Subscription to raise £650,000
English 29.8 KB
2020-01-15 13:30
HEMO's CAR-T Cells Effective Against AML in vitro
English 20.7 KB
2019-11-18 08:00
Operational Update
English 21.0 KB
2019-11-12 08:00
Presentation at the Investival Showcase
English 17.7 KB
2019-11-06 08:00
Presentation at the NY Oncology Investor Conf.
English 17.1 KB
2019-10-23 09:00
Research Agreement with Global Pharma Company
English 19.2 KB
2019-10-21 09:00
Presentation at NY Stem Cell Foundation conference
English 18.2 KB
2019-09-30 09:00
Half-year Report
English 158.4 KB
2019-09-12 09:00
Hemogenyx scientific advisor receives Lasker Award
English 20.0 KB
2019-08-01 09:00
Total Voting Rights
English 16.8 KB
2019-07-12 09:00
CDX Patent Application
English 18.4 KB

Automate Your Workflow. Get a real-time feed of all HEMOGENYX PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HEMOGENYX PHARMACEUTICALS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HEMOGENYX PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.